|
US 11,786,584 B2 |
|
| Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); Harpreet Singh, Munich (DE); Phillip Mueller, Kassel (DE); Julia Leibold, Langkampfen (AT); and Valentina Goldfinger, Tuebingen (DE) |
| Assigned to Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed on May 14, 2021, as Appl. No. 17/320,929. |
| Application 17/320,929 is a continuation of application No. 17/017,281, filed on Sep. 10, 2020, granted, now 11,065,315. |
| Application 17/017,281 is a continuation of application No. 16/552,873, filed on Aug. 27, 2019, granted, now 10,799,569, issued on Oct. 13, 2020. |
| Application 16/552,873 is a continuation of application No. 16/385,221, filed on Apr. 16, 2019, granted, now 10,449,238, issued on Oct. 22, 2019. |
| Application 16/385,221 is a continuation of application No. 15/849,878, filed on Dec. 21, 2017, granted, now 10,500,259, issued on Dec. 10, 2019. |
| Application 15/849,878 is a continuation of application No. 15/229,970, filed on Aug. 5, 2016, granted, now 9,908,920, issued on Mar. 6, 2018. |
| Claims priority of provisional application 62/201,289, filed on Aug. 5, 2015. |
| Claims priority of application No. 1513921 (GB), filed on Aug. 6, 2015. |
| Prior Publication US 2021/0275654 A1, Sep. 9, 2021 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01) |